ReviewPharmaceutics2023
Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 129 citations in OpenAlex.
- Single-Step Solvent Evaporation Via Spray-Drying for the Production of Ph-Sensitive Polymeric Nanospheres for Dermatological Applications.AAPS PharmSciTech · 2026Article
- Bioinspired Injectable Thermosensitive Gallic Acid-Conjugated Hyaluronic Acid/Pluronic Hydrogels to Prevent Postoperative Adhesion.Biomimetics (Basel, Switzerland) · 2026Article
- Wearable OLED-Assisted Photodynamic Cancer Therapy Using Chlorin e6-Loaded Pluronic Nanocapsules as Photosensitizers.Advanced healthcare materials · 2026Article
- Breaking the Solubility-Permeability Tradeoff: Surfactant-Mediated Enhancement of Oral Etoposide Absorption.Biomolecules · 2026Article
- Combination Therapeutic Delivery Systems.Pharmaceutics · 2026Article
- Optimization of the Nanoparticle Yield and Physicochemical Properties by a Structured Study of Nanoprecipitation Process Parameters.ACS omega · 2026Article
- Breaking the Efflux Barrier: P-Glycoprotein and Emerging Strategies to Overcome Multidrug Resistance in Cancer.Cancers · 2026Review
- From Solvent-Mediated Micellization to Packing in a Face-Centered Cubic Structure of Poloxamers.Macromolecules · 2026Article
- Nanostructured Lipid Carriers Enable In Vivo Efficacy of Parthenolide inPharmaceutics · 2026Article
- Micelle-Based Ocular Inserts for Sustained Delivery and Improved Corneal Permeation of Rebamipide in Dry Eye Disease.Pharmaceutics · 2026Article
- Article
- Development and Ex Vivo Evaluation of a Thermoreversible Silver Nanoparticle-Loaded Gel as a Biocompatible Intracanal Medicament.Journal of functional biomaterials · 2026Article
- Modulating nuclear stiffness and envelope barrier facilitates AAV nuclear entry and reduces immunogenicity.Nature communications · 2026Article
- Matrix-Dependent Stability and Antibacterial Efficacy of Silver Nanoparticles: A Comparative Study of Anionic Carbopol vs. Non-Ionic Pluronic Hydrogels.Pharmaceutics · 2026Article
- Enhanced ocular delivery of brinzolamide via β-cyclodextrin-based micelles for glaucoma management.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Advanced hybrid-stabilized cinacalcet nanocrystals for enhanced oral bioavailability: formulation and integratedFrontiers in pharmacology · 2026Article
- Functional reprogramming of melittin by PluronicFrontiers in oncology · 2026Article
- Natural Powerhouse Duo: Hierarchical Levan Hydrogels with Nanoencapsulated Cannabidiol as Local Delivery Systems.Pharmaceutical research · 2025Article
- Overcoming Oral Cavity Barriers for Peptide Delivery Using Advanced Pharmaceutical Techniques and Nano-Formulation Platforms.Biomedicines · 2025Review
- Ultrasonic-Responsive Pluronic P105/F127 Nanogels for Overcoming Multidrug Resistance in Cancer.Gels (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Pluronics are amphiphilic triblock copolymers composed of two hydrophilic poly (ethylene oxide) (PEO) chains linked via a central hydrophobic polypropylene oxide (PPO). Owing to their low molecular weight polymer and greater number of PEO segments, Pluronics induce micelle formation and gelation at critical micelle concentrations and temperatures. Pluronics F-68 and F-127 are the only United States (U.S.) FDA-approved classes of Pluronics and have been extensively used as materials for living bodies. Owing to the fascinating characteristics of Pluronics, many studies have suggested their role in biomedical applications, such as drug delivery systems, tissue regeneration scaffolders, and biosurfactants. As a result, various studies have been performed using Pluronics as a tool in nanomedicine and targeted delivery systems. This review sought to describe the delivery of therapeutic cargos using Pluronic F-68 and F-127-based cancer nanomedicines and their composites for combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.